LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Home・Elenco Azioni・Erasca Inc

Erasca Inc

Chiusa

13.81 7.81

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

12.81

Massimo

14.97

Metriche Chiave
By Trading Economics
Entrata	-154M -183M
EPS	-0.6
Dipendenti	103
EBITDA	-5.3M -37M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+57.87% upside

Dividendi
By Dow Jones
Utili prossimi	10 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	249M 3.5B
Apertura precedente	6
Chiusura precedente	13.81

Erasca Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 giu 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 giu 2026, 23:38 UTC

Acquisizioni, Fusioni, Takeovers

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 giu 2026, 23:37 UTC

Discorsi di Mercato

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 giu 2026, 23:01 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

1 giu 2026, 23:01 UTC

Discorsi di Mercato

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 giu 2026, 22:08 UTC

Acquisizioni, Fusioni, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 giu 2026, 22:01 UTC

Acquisizioni, Fusioni, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 giu 2026, 22:01 UTC

Acquisizioni, Fusioni, Takeovers

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 giu 2026, 21:55 UTC

Acquisizioni, Fusioni, Takeovers

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 giu 2026, 21:53 UTC

Discorsi di Mercato

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 giu 2026, 21:22 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 giu 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

1 giu 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

1 giu 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

1 giu 2026, 20:46 UTC

Acquisizioni, Fusioni, Takeovers

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 giu 2026, 20:22 UTC

Acquisizioni, Fusioni, Takeovers

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 giu 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 giu 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Array Digital Infrastructure Declares $11 Special Div

1 giu 2026, 20:20 UTC

Acquisizioni, Fusioni, Takeovers

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 giu 2026, 19:40 UTC

Discorsi di Mercato

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 giu 2026, 19:28 UTC

Discorsi di Mercato

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 giu 2026, 19:01 UTC

Discorsi di Mercato

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 giu 2026, 18:58 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 giu 2026, 18:54 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 giu 2026, 18:33 UTC

Discorsi di Mercato

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 giu 2026, 18:32 UTC

Discorsi di Mercato

Precious Metals Fall to Start June -- Market Talk

1 giu 2026, 18:00 UTC

Acquisizioni, Fusioni, Takeovers

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 giu 2026, 17:18 UTC

Discorsi di Mercato

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 giu 2026, 17:18 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

1 giu 2026, 17:10 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Confronto tra pari

Modifica del prezzo

Erasca Inc Previsione

Obiettivo di Prezzo

By TipRanks

57.87% in crescita

Previsioni per 12 mesi

Media 20.27 USD 57.87%

Alto 30 USD

Basso 9 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Erasca Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Erasca Inc - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.